A multi-regional, randomized evaluation of the lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in patients with hypercholesterolemia or low HDL-C
Event:
ESC Congress 2016
Topic:
Drug therapy
Session:
Lipid-lowering agents - New perspectives
